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Edited by Jesus AvilaAbstract Huntingtons and Parkinsons diseases are both neu-
rodegenerative disorders caused at least in part by misfolding
and aggregation of huntingtin (htt) and a-synuclein, respectively.
Here we use a single chain antibody fragment (scFv) isolated
against oligomeric a-synuclein to probe similarities and diﬀer-
ences between the aggregation and toxic mechanisms of htt
and a-synuclein. When incubated with htt, the scFv both blocks
formation of and promotes dissociation of ﬁbrillar aggregates,
but stabilizes formation of cytotoxic oligomeric aggregates. Pre-
vious studies with monomeric a-synuclein showed the scFv pre-
vented ﬁbrillar aggregation, but blocked toxicity of oligomeric
aggregates. These divergent eﬀects suggest the toxic mechanisms
of oligomeric aggregates diﬀer among amyloidogenic protein
species.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Toxicity1. Introduction
Huntingtons disease (HD) is a neurodegenerative disorder
caused by expansion of a polyglutamine (PolyQ) region in
exon1 of the protein huntingtin (htt) [1] to contain 36 or more
glutamine residues [2], where the age of HD onset decreases
with increasing length of the PolyQ region [3]. Htt ultimately
forms insoluble ﬁbrillar aggregates similar to other amyloido-
genic proteins [4]. Htt variants containing PolyQ repeats above
the pathological threshold of 36 residues form ﬁbrillar nuclear
inclusions in the brains of transgenic mouse models of HD and
in individuals with HD [5].
Increasing evidence indicates the ﬁbrillar aggregates are not
the toxic species in HD [6] and other amyloid diseases [7], but
rather toxicity is induced by intermediate soluble oligomeric
species [4,8,9]. Anti-oligomeric polyclonal antibodies were
shown to recognize aggregates of a variety of diﬀerent proteins
including PolyQ, b-amyloid and a-synuclein and to inhibitAbbreviations: scFv, single chain variable domain antibody fragment;
AFM, atomic force microscopy; LDH, lactate dehydrogenase; HD,
Huntingtons disease; SDS–PAGE, sodium dodecylsulfate–polyacryl-
amide gel electrophoresis; ThS, Thioﬂavine S
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doi:10.1016/j.febslet.2008.01.014their toxicity [10] suggesting common structural elements and
pathological mechanisms, possibly through membrane perme-
abilization [11].
Here we demonstrate that a single chain variable domain
antibody fragment (scFv) isolated against an oligomeric form
of a-synuclein [12] also interacts with oligomeric forms of htt-
Exon1 containing 51 glutamine repeats (htt51Q). Similar to
the results previously obtained with a-synuclein, the scFv stabi-
lizes formation of oligomeric htt51Q aggregates starting from
either the monomeric or ﬁbrillar form, but the scFv greatly in-
creases the cytotoxicity of the resulting oligomeric aggregates in
sharp contrast to results obtained previously with a-synuclein.2. Materials and methods
2.1. GST-htt51Q plasmid transformation into Escherichia coli DH-5a
Glutathione S-transferase httExon1-51Q (GST-htt51Q) plasmid
constructs were generously provided by Dr. Leslie Thompson (UC Ir-
vine) and transformed into E. coli DH-5a cells for protein expression.
2.2. GST-htt51Q protein expression and puriﬁcation
E. coli DH-5a cells were grown, protein expression was induced, and
protein puriﬁed from cell extract using glutathione agarose beads
essentially as described [13]. Typical yields were 0.3–0.5 mg/ml of
GST-htt51Q. Purity was determined by 12.5% sodium dodecylsul-
fate–polyacrylamide gel electrophoresis (SDS–PAGE) and a 54 kDa
band corresponding to monomeric GST-htt51Q fusion construct was
observed as previously reported [13].
2.3. Puriﬁcation of scFv
Soluble D5 scFv and a control scFv isolated against Phosphorylase
B (aPLB) were produced and puriﬁed essentially as described [12]. Pur-
ity of the scFvs were veriﬁed by 12.5% SDS–PAGE.
2.4. htt51Q aggregation
Puriﬁed GST-htt51Q was dialyzed overnight against 40 mM Tris–
HCl (pH 8.0), 150 mM NaCl, 0.1 mM EDTA, 1 mM CaCl2, and 5%
(v/v) glycerol, and passed though a 0.2 lm ﬁlter. GST-htt51Q was di-
luted to 2 lM, and the GST tag was removed using trypsin at a 1:1000
(w/w) enzyme to substrate ratio at 37 C. The reaction was stopped
after 30 min by addition of PMSF (1 mM). htt51Q was incubated at
37 C alone or with D5 scFv. D5 was added at a scFv to htt51Q molar
ratio of 1:2. Samples were taken at 0, 1, 3, 24, and 48 h after addition
of trypsin. For pre-aggregated samples, 51Q was allowed to aggregate
for 24 h and D5 was then added at a scFv to htt51Q ratio of 1:2. Sam-
ples were collected at 24, 30, and 48 h.
2.5. Thioﬂavine S (ThS) ﬂuorescence
Aggregation of htt51Q was measured using a 25 lM solution of ThS
(Sigma) in PBS pH 7.4. A 25 ll sample was added to 2 ml of ThS
solution, and ﬂuorescence intensity was measured with a Shimadzublished by Elsevier B.V. All rights reserved.
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length of 430 and 510 nm, respectively. Data were recorded as the
mean of three repeated measurements after the background ﬂuores-
cence of ThS alone was subtracted.2.6. LDH release assay
Cytotoxicity was measured using lactate dehydrogenase (LDH) re-
lease as described previously [14]. Human neuroblastoma cells, SH-
SY5Y, were incubated for 24 h to allow attachment to the bottom of
wells. Media was replaced with serum free media containing 25 ll of
htt51Q samples with or without scFv to a total volume of 100 ll. Plates
were incubated for 48 h. LDH release was measured with an LDH re-
lease toxicity kit (Sigma). Absorbance was measured as the diﬀerence
between 490 nm and 690 nm using a Wallac 1420 plate reader (Perkin
Elmer). The data are reported as percentage of LDH released com-
pared to LDH released from wells with media alone. This LDH assay
measuring cytotoxicity of SH-SY5Y cells consistently agrees with other
cell toxicity assays performed in our lab, including MTT and blue try-
pan assays [12,14], and visual inspection also conﬁrmed an increase in
dead cell count in wells showing an increase in LDH activity.2.7. Atomic force microscopy (AFM) imaging
A 10 ll aliquot of each sample was deposited on cleaved mica and
imaged as previously described [12]. The sample scan size used was
5 lm by 5 lm, and the image resolution was 512 samples per line.Fig. 1. Eﬀect of D5 and control (aPLB) scFvs on aggregation and cytotoxic
scFvs was monitored using Thioﬂavin S (A). Cytotoxicity of the aggregation
Data are presented as the percentage of LDH released compared to cells i
independent experiments, *P < 0.05, **P < 0.01) was determined by ANOVA3. Results
3.1. D5 scFv alters normal htt51Q aggregation and toxicity
The scFv D5 was previously isolated by panning against
oligomeric a-synuclein, and was shown to speciﬁcally bind to
a-synuclein oligomers, inhibit formation of ﬁbrillar a-synuc-
lein, and to prevent toxic aggregation of a-synuclein as well
as toxicity of preformed a-synuclein oligomers against the neu-
roblastoma cell line SH-SY5Y [12]. For htt aggregation stud-
ies, the GST tag of the fusion protein GST-htt51Q (2 lM)
was removed by trypsin digestion. For aggregation studies
with scFv, an aliquot of D5 was added at a ﬁnal concentration
of 1 lM after trypsin digestion. Aliquots were removed to
monitor aggregation by ThS ﬂuorescence and AFM. When
htt51Q is incubated alone ThS ﬂuorescence of 51Q increases
with time, indicating the formation of ﬁbrillar htt51Q, until
a maximum is reached after 24 h (Fig. 1A). However, when
htt51Q is incubated with the D5 scFv, a signiﬁcant decrease
in aggregation compared to htt51Q alone is observed. AFM
images conﬁrm the ThS ﬂuorescence results where small aggre-
gates are seen at 0, 1, and 3 h time points of htt51Q samples
incubated both with and without D5 (Fig. 2). The 24 h timeity of htt51Q. Aggregation of htt51Q with and without D5 and aPLB
samples toward SH-SY5Y cells was determined by LDH release (B).
ncubated in wells containing no htt51Q. Statistical signiﬁcance (four
using Minitab statistical software.
Fig. 2. AFM images of htt51Q with and without D5 and control scFvs. Aggregation of htt51Q was induced as described both with and without D5
and control scFvs. Samples of htt51Q alone were taken at 0 h (A), 1 h (B), 3 h (C), and 24 h (D) after the cleavage of the GST tag. Samples containing
htt51Q incubated along with D5 were taken at 1 h (E), 3 h (F) and 24 h (G) after the cleavage. A sample of htt51Q and aPLB was also taken at 24 h
(H). Images were obtained using AFM in tapping mode. Scale bars represent 1 lm and the inset scale bar in (G) represents 125 nm.
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gates for htt51Q without added D5 as commonly seen with htt
above the pathological PolyQ repeat threshold [13], while the
same sample co-incubated with D5 shows no ﬁbrillar aggre-
gates, but rather many small oligomeric aggregates. Samples
of htt51Q co-incubated with the control scFv, aPLB, did not
diﬀer signiﬁcantly from the htt51Q alone samples when exam-
ined either with ThS ﬂuorescence (Fig. 1A) or AFM (Fig. 2).
To test for cytotoxic eﬀects of the aggregates, aliquots of the
aggregated htt51Q samples with and without D5 scFv wereincubated with the human neuroblastoma cell line SH-SY5Y
for 48 h. Since a-synuclein and htt aggregates aﬀect diﬀerent
brain regions, non-diﬀerentiated SH-SY5Y cells were utilized
to allow us to directly compare results obtained with the diﬀer-
ent proteins. Samples containing htt51Q alone showed signiﬁ-
cant toxicity only with the 3 h aliquot (Fig. 1B), for which
numerous small aggregate structures are observed by AFM.
The branched ﬁbrillar aggregates of htt51Q alone observed
after 24 h do not induce toxicity. In contrast, when htt51Q
was co-incubated with D5, after 24 h signiﬁcant toxicity
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ThS staining or AFM. The control scFv, aPLB, was previously
shown not to aﬀect cell toxicity of SH-SY5Y cells [12].
3.2. D5 dissolves preformed htt51Q Fibrils into smaller toxic
aggregates
We next studied whether the anti-oligomeric scFv would
alter the structure of preformed htt51Q ﬁbrils. A sample of
htt51Q (2 lM) was pre-aggregated for 24 h to generate
branched ﬁbrillar htt. An aliquot of D5 scFv (1 lM ﬁnal con-
centration) was then added to the htt51Q, and ﬁbrillar content
and aggregation were monitored with ThS ﬂuorescence and
AFM imaging. When incubated alone, the ﬂuorescence read-
ings maintained a consistently high value after pre-aggregation
(Fig. 3A). However, when incubated with D5, the samples
show a signiﬁcant decrease in ﬂuorescence after 6 and 24 h
of preformed ﬁbril and D5 co-incubation. Dissolution of the
ﬁbrils is veriﬁed in the AFM images where the samples of
htt51Q incubated alone shows continued formation of long
branched aggregates characteristic of htt ﬁbrils (Fig. 4), while
samples co-incubated with D5 at the 6 and 24 h time pointsFig. 3. Eﬀect of D5 on preformed htt51Q ﬁbrils. D5 was added to pre-
aggregated htt51Q at 24 h and the eﬀect on the ﬁbrils was monitored
with ThS (A). The eﬀects on cytotoxicity were studied using LDH
release with SH-SY5Y cells. Data are shown as the percentage of LDH
released by cells incubated in wells containing no htt51Q samples (B).
Statistical signiﬁcance (three independent experiments, *P < 0.05,
***P < 0.001) was determined by ANOVA using Minitab statistical
software.show complete dissociation of the preformed ﬁbrils into
numerous small aggregates.
We then tested whether the oligomeric aggregates formed
from dissociation of ﬁbrils were toxic to SH-SY5Y neuronal
cells. While the ﬁbrillar htt51Q aggregates were not toxic to
SH-SY5Y cells at any of the time points studied (Fig. 3B),
the smaller oligomeric aggregates derived from the dissociation
of htt51Q ﬁbrils when co-incubated with D5 were extremely
toxic to the cells (Fig. 3B). While D5 was shown to bind only
to oligomeric forms of a-synuclein [12], it was not possible to
show a similar speciﬁcity for oligomeric htt51Q by ELISA or
dot blot due to the very fast aggregation of htt51Q and the het-
erogenous aggregation population resulting from cleavage of
the htt-GST construct. However since D5 stabilizes formation
of oligomeric htt51Q morphologies regardless of whether
monomeric or ﬁbrillar htt51Q is used as a starting point, and
control scFvs do not have any eﬀect on either form, it is clear
the D5 either directly or indirectly stabilizes formation of toxic
oligomeric htt51Q aggregates.4. Discussion
An anti-oligomer antibody preparation was shown to pre-
vent aggregation and toxicity of various proteins related to
amyloid diseases, including a-synuclein (Parkinsons disease)
and PolyQ (Huntingtons disease), suggesting that to at least
some extent these diseases may all share a common toxic mech-
anism [10]. However, the results we present here indicate that
while toxic oligomers may share similar structural features,
at least some distinct diﬀerences in toxic mechanisms do exist.
The anti-oligomeric scFv, D5, isolated against a-synuclein
oligomers binds and stabilizes oligomeric a-synuclein aggre-
gates, prevents ﬁbril formation, and also prevents in vitro cyto-
toxicity against SH-SY5Y cells when the scFv is incubated
with monomeric and preformed oligomeric a-synuclein forms
[12]. When D5 is incubated with htt51Q, it also prevents for-
mation of ﬁbrillar aggregates similar to what is observed with
a-synuclein; however, it greatly increases toxicity to SH-SY5Y
cells. When D5 is incubated with preformed htt51Q ﬁbrils it
dissociates the ﬁbrils into smaller oligomeric species that are
toxic to SH-SY5Y cells. These results indicate that D5 stabi-
lizes oligomeric htt51Q forms in a manner that is toxic to cells
while it binds oligomeric a-synuclein in a manner that blocks
toxicity. Because D5 alters the aggregation of both htt51Q
and a-synuclein similarly, but the in vitro toxicity quite diﬀer-
ently, these studies provide evidence that toxic oligomeric spe-
cies may interact with cells and cellular function in diﬀerent
ways.
The results we report here are somewhat in disagreement
with results from previous studies that suggested anti-oligomer
antibodies rescued oligomer induced toxicity from a variety of
diﬀerent proteins including PolyQ [10]. A potential explana-
tion for this discrepancy is the previous studies utilized poly-
clonal anti-oligomer antibody preparations, while we used a
monovalent monoclonal scFv. A polyclonal antibody mixture
may bind to diﬀerent regions on the oligomeric aggregates, and
because of their larger size and bivalency may block toxic
interactions with cells, whereas the scFvs used here all bind
the same epitope. Another diﬀerence that may explain the
divergent results is that we utilized Exon1 of the huntingtin
gene containing 51 glutamines in the current study, where
Fig. 4. AFM images of D5 incubated with preformed 51Q ﬁbrils. htt51Q was allowed to aggregate into ﬁbrils for 24 h before the addition of D5.
Samples of htt51Q aggregates without D5 were taken at 0 h (A), 6 h (B), and 24 h (C) after the initial 24 h pre-aggregation time. Samples of
preformed htt51Q ﬁbers with D5 were taken at 0 h (D), 6 h (E), and 24 h (F) after the initial 24 h pre-aggregation time and the addition of D5. Scale
bars represent 1 lm.
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ﬂanked by two lysines on each side, so the additional htt resi-
dues may facilitate toxic interactions with cells. Finally, it is
also possible that the diﬀerent anti-oligomer antibody prepara-
tions simply bind to diﬀerent areas of the oligomers aﬀecting
toxicity diﬀerently.
Antibodies and scFv antibody fragments, like D5, have
great potential in the treatment and characterization of neuro-
degenerative diseases. With b-amyloid, a protein implicated in
Alzheimers disease, monoclonal antibodies [15] and scFvs
[14,16] have been shown to control aggregation and toxicity.
Also, scFvs produced intracellularly can control toxicity of
both a-synuclein [17] and huntingtin [18]. However, the results
we present here indicate that caution must be used in adminis-
tering a therapeutic that protects against one amyloid disease
since it may not necessarily protect against other amyloido-
genic diseases, and may potentially exacerbate them. The
cross-reactivity potential of amyloid disease therapeutics with
other amyloid proteins should be rigorously studied to avoid
potential harmful eﬀects [5].Acknowledgements: This work was supported by grants from the High
Q Foundation, Michael J. Fox Foundation and Arizona Biomedical
Research Commission.References
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